Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

SIGA vs EBS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SIGA Captures Overall Composite Edge (47.5 HOLD vs 42.6 HOLD), While EBS Leads 3–2 on Growth & Valuation Pillars

SIGA Overall Winner 6-Pillar Tally: SIGA 2 – 3 EBS (1 Tie) Matrix Metrics: SIGA 5 – 5 EBS

As of Nov 19, 2026, SIGA Technologies Inc. (SIGA) captures the overall head-to-head institutional edge over Emergent Biosolutions, Inc. (EBS) on higher Unified Composite conviction (47.5/100 HOLD vs. 42.6/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while EBS wins 3–2 across the 6-pillar growth and valuation breakdown. SIGA trades at $2.65 (2.5x Forward P/E, -14.2% operating margin) versus EBS at $5.15 (19.3x Forward P/E, 5.8% operating margin).

  • Growth vs. Quality Trade-Off: SIGA earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. EBS 42.6/100 HOLD) and 0.75β · 65% Vol risk profile, whereas EBS leads top-line expansion (-52.4% YoY revenue growth, 0.38x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile EBS is in a Breakdown options structure phase (RSI 29.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SIGA vs EBS
SIGA NASDAQ Head-to-Head Winner
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.65
-5.36% 1D
Market Cap $187.9M
TTM Revenue $52M
Forward P/E 2.5x
Beta / 30D Vol 0.75β · 65% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.7%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $3.02 · SMA50: $3.14
EBS NYSE
Emergent Biosolutions, Inc.
Pharmaceutical Preparations
$5.15
-6.36% 1D
Market Cap $282.8M
TTM Revenue $649M
Forward P/E 19.3x
Beta / 30D Vol 0.90β · 54% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 51.0 Flow 67.0 Mom 59.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 29
RSI-14: 29.2 · SMA20: $6.14 · SMA50: $6.47

6-Pillar Scorecard Institutional Category Breakdown (SIGA 2 – 3 EBS)

Columns: Metric · SIGA · EBS
1. Valuation Multiples EBS
Forward P/E 2.5x 19.3x
Trailing P/E N/M 19.3x
PEG Ratio 3.37x 0.38x
EV / Revenue 1.4x 0.9x
2. Growth & Scale SIGA
Revenue Growth (YoY) -49.7% -52.4%
Earnings Growth (YoY) -65.3% -93.8%
TTM Revenue (USD) $52M $649M
Market Cap $187.9M $282.8M
3. Profitability & Quality EBS
Gross Margin 23.4% 43.4%
Operating Margin -14.2% 5.8%
Net Profit Margin 1.3% -40.2%
Return on Equity (ROE) 0.4% -58.2%
4. Balance Sheet & Cash Flow EBS
Cash Generation (TTM) -$12M $188M
Cash Flow Margin -22.1% 29.0%
Net Cash / Leverage $116M Net Cash $332M Net Debt (1.62x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SIGA
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 81.4% (8th %ile) 84.5% (5th %ile)
Put/Call OI Skew 0.04x (Call-Skewed) 2.48x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity 37.6% of Rev ($20M) 37.6% of Rev ($244M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SIGA (5) vs EBS (5)
Institutional Metric SIGA EBS Criterion Row Edge
Market Capitalization
Scale
$187.9M $282.8M Larger Scale EBS
Trailing P/E Ratio
Valuation
N/M 19.3x Lower Multiple EBS
Forward P/E Ratio
Valuation
2.5x 19.3x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
-49.7% -52.4% Higher Growth SIGA
Operating Margin (TTM)
Profitability
-14.2% 5.8% Higher Margin EBS
Net Profit Margin
Profitability
1.3% -40.2% Higher Margin SIGA
Return on Equity (ROE)
Capital Efficiency
0.4% -58.2% Higher ROE SIGA
52-Week Range Position
Momentum
3% ($3–$7) 8% ($4–$14) Stronger Trend EBS
Beta / 30D Volatility
Risk Regime
0.75β · 65% Vol 0.90β · 54% Vol Lower Realized Risk EBS
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite SIGA
Trailing 12M Revenue (USD)
Operating Scale
$52M $649M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% 43.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.37x PEG · 1.4x EV/Rev 0.38x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($116M Net Cash) $188M ($332M Net Debt (1.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SIGA +1.88 pp
SIGA: -15.06% · EBS: -16.94%
3M Horizon EBS +14.21 pp
SIGA: -12.83% · EBS: +1.38%
6M Horizon EBS +5.27 pp
SIGA: -43.74% · EBS: -38.47%
1Y Horizon EBS +6.5 pp
SIGA: -55.61% · EBS: -49.11%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SIGA Revenue EBS Revenue SIGA Op. Margin EBS Op. Margin Margin Leader
FY2018 $480M $780M 74.4% 11.5% SIGA
FY2019 $30M $1.11B -8.7% 10.3% EBS
FY2020 $120M $1.56B 67.6% 28.2% SIGA
FY2021 $130M $1.77B 66.7% 19.2% SIGA
FY2022 $110M $1.12B 38.5% -15.2% SIGA
FY2023 $140M $1.05B 59.8% -69.2% SIGA
FY2024 $140M $1.04B 50.4% -10.4% SIGA
FY2025 $90M $740M 25.1% 13.5% SIGA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SIGA CONSOLIDATION
33d in phase · OBV DISTRIBUTION
Current IV 81.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EBS BREAKDOWN
33d in phase · OBV DISTRIBUTION
Current IV 84.5%
IV Percentile 5th %ile
Put/Call OI Skew 2.48x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact EBS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $5.81 · IV 78.8%

EBS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($581)

Compare $581 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 78.8% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $6 / $7 Bull Call Spread

Buy 4x $6C · Sell 4x $7C · 32d

Net Entry $180 Debit
T+5d @ +5% Move +$21 (+12%)
Max Risk / Buffer $180 Capped
5d Edge & Liquidity 0.4x R:R · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $5P / $6-$7C Seagull

Sell 2x $5P · Buy 2x $6/$7C · 32d

Net Entry $60 Debit
T+5d @ +5% Move +$27 (+14.0% RoM)
Max Risk / Buffer -13.9% Put Cushion ($190 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published
EBS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $282.8M market capitalization and 5.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($244M)
90D Engineering Disclosures 0 Published

Investor FAQ SIGA vs EBS Key Questions & Quantitative Answers

As of Nov 19, 2026, SIGA Technologies Inc. (SIGA) captures the overall head-to-head institutional edge over Emergent Biosolutions, Inc. (EBS) on higher Unified Composite conviction (47.5/100 HOLD vs. 42.6/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while EBS wins 3–2 across the 6-pillar growth and valuation breakdown. SIGA trades at $2.65 (2.5x Forward P/E, -14.2% operating margin) versus EBS at $5.15 (19.3x Forward P/E, 5.8% operating margin). Growth vs. Quality Trade-Off: SIGA earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. EBS 42.6/100 HOLD) and 0.75β · 65% Vol risk profile, whereas EBS leads top-line expansion (-52.4% YoY revenue growth, 0.38x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile EBS is in a Breakdown options structure phase (RSI 29.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SIGA leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with EBS at -52.4% YoY revenue growth and -93.8% YoY earnings growth on $649M TTM revenue (43.4% gross margin, 5.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIGA cumulative revenue shifted -81.2% while EBS shifted -5.1%. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($244M) (0 disclosures) for EBS.

EBS screens cheaper on headline valuation multiples. SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas EBS trades at 19.3x Forward P/E, 19.3x Trailing P/E, 0.38x PEG, and 0.9x EV/Revenue (29.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus EBS (-58.2% ROE) capital efficiency.

In options market volatility and institutional positioning, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk). By comparison, EBS carries 84.5% implied volatility (5th %ile, Compressed (<25th %ile)), a 2.48x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.90β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.